Pelthos Therapeutics Inc.
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $16.8M
- Net income
- -$43.3M
- Total assets
- $130.4M
- Market cap
- $88.8M
- Gross margin
- 76.3%
- Operating margin
- -193.1%
- Net margin
- -257.9%
Source: SEC EDGAR · updated Jun 7, 2026
Financial statements
Income statement
- Revenue
- $16.8M
- Cost of revenue
- $4.0M
- Gross profit
- $12.8M
- Operating expenses
- $45.2M
- Operating income
- -$32.4M
- Income tax
- -$7.4M
- Net income
- -$43.3M
- EPS (basic)
- $-23.04
- EPS (diluted)
- $-23.04
Balance sheet
- Total assets
- $130.4M
- Current assets
- $53.4M
- Total liabilities
- $91.5M
- Current liabilities
- $26.0M
- Shareholders’ equity
- $38.9M
Cash flow
- Operating cash flow
- -$22.6M
- Investing cash flow
- -$5.2M
- Financing cash flow
- $45.3M
- Net cash flow
- $17.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $88.8M
- EPS (diluted)
- $-23.04
- Shares outstanding
- 3.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 16, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $43.3M in FY2025.
- Gross margin of 76.3%, net margin -257.9%.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Pelthos Therapeutics Inc..
Write a review
News about Pelthos Therapeutics Inc.
News & sentiment via Polygon.io
